Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial

What is it about?

Aspirin-exacerbated respiratory disease (AERD) is characterized by asthma, chronic rhinosinusitis, nasal polyposis, and lifelong hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs). A randomized study was planned to evaluate the efficacy of omalizumab, an anti-immunoglobulin E antibody, against AERD. Omalizumab rapidly improved asthma-and nasal-related symptoms and induced NSAIDs tolerance in more than half of the participants after only 3 months of treatment.

Featured Image